Clinical trials based on the Stroke Riskometer
Welcome to the Stroke Riskometer app and the RIBURST study.
On this page, you can:
- Join the RIBURST study as a scientific collaborator
- Request permission to use the Stroke Riskometer for your study
- Register your study based on the Stroke Riskometer
- Find a past or current study that is using the Stroke Riskometer
- App-related resources
- Contact us
NOTE: If you use the Stroke Riskometer data or app in your research you must acknowledge this in any relevant publications or presentations. Please use the following wording: “We acknowledge the use of Stroke Riskometer data /the Stroke Riskometer app in this study. The Stroke Riskometer app was developed by and is copyrighted by Auckland University of Technology, Auckland, New Zealand”.
Find a past or current study that is using the Stroke Riskometer
Find out which other studies have been or are being carried out based on the Stroke Riskometer app. For more information, contact the lead investigator.
- Project: PERsonalised Knowledge to reduce the risk of Stroke (PERKS-International)
- Start date: 2021
- End date: 2024
- Lead Investigator: Associate Professor Seana Gall - Menzies Institute for Medical Research, University of Tasmania. Menzies Institute for Medical Research, University of Tasmania, Hobart 7005, Australia. T =+61 3 6226 4728 E= email@example.com
- Abstract: This is a Phase III, prospective, pragmatic, open-label, single blinded endpoint 2 arm randomised controlled trial (RCT) including 790 participants across Australia and New Zealand. Participants will be adults aged >35 and ≤75 years with two or more modifiable risk factors (smoking, overweight, low physical activity, poor diet, high blood pressure, high total cholesterol or high blood glucose) measured using the Life's Simple 7 (LS7) index. Participants will be randomised using a stratified block approach to either the intervention or usual care group. Participants in the intervention group will be provided with the Stroke Riskometer App whereas those in the usual care group will not be informed about the Stroke Riskometer App. Blinded assessments will be conducted face-to-face at baseline and 6 months and by online or telephone assessment at 3 and 12 months. The primary outcome is a 0.4 point increase in the total LS7 score from baseline to 6 months post-randomisation in the intervention compared to usual care group.
- Project: Reducing the International Burden of Stroke Using Mobile Technology): The Stroke Riskometer research project (RIBURST
- Start date: 2014
- Lead Investigator: Professor Valery Feigin, National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand. Efirstname.lastname@example.org
- Coordinating Investigator: Dr Alexander Merkin, Auckland University of Technology, New Zealand. NISAN, AUT University, Private Bag 92006, Auckland 1142, New Zealand. Eemail@example.com
- Abstract: RIBURST is an international collaborative study that aims to better understand the risk factors associated with stroke, heart attack, dementia and diabetes mellitus and to assess how much influence each risk factor has on the likelihood of having a stroke, heart attack, dementia and diabetes mellitus in the future. The Stroke Riskometer app already involves over 300 renowned stroke experts from 102 countries making it the largest international collaborative mobile health project in the world.
- Project: Mobile Application to Reduce Risk of Stroke (MARS)
- Start date: 2016
- End date: 2019
- Lead investigator: Professor Valery Feigin, National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand. Efirstname.lastname@example.org
- Abstract: The MARS trial was a pragmatic pilot, open-label, 2-arm prospective RCT. Consented participants were randomly assigned to the intervention arm using online minimization randomization. Usual care participants were not actively informed about the App. Changes in lifestyle behavior were measured at baseline, 3- and 6-months and assessed using Life’s Simple 7 (LS7) questionnaire as recommended by the American Heart Association. Questions about stroke symptoms and risk factors were asked to measure awareness levels. Positive feedback was received from study participants for the App as a tool to know more about stroke and take action for better health. Conclusions: The findings suggest the Stroke Riskometer is a feasible intervention for stroke awareness and prevention, and the results indicated that a full scale RCT to test the effectiveness of the app was warranted.
For information about the app or the RIBURST study, contact the project manager at email@example.com